Principales cambios en las Recomendaciones para la Resucitación del Consejo Europeo de Resucitación (ERC) 2015.

RESUMEN: Recientemente se han publicado las nuevas guías referentes a la Reanimación Cardiopulmonar (RCP) por parte del European Resuscitation Council (ERC). El mismo día, el Consejo Español de Resucitación Cardiopulmonar (CERCP) emitía una declaración oficial para manifestar su adhesión a estas recomendaciones. Esta misma declaración menciona “la necesidad de la aplicación ajustada de estas recomendaciones europeas, tanto en el ámbito asistencial como en el de la formación”. Aunque se mantienen la mayoría de las recomendaciones publicadas en el año 2010, es preciso conocer estos cambios para ajustarse a los nuevos conocimientos científicos. Para ello, este documento pretende resumir los principales cambios respecto a las recomendaciones anteriores con el objetivo de proporcionar una primera aproximación a los profesionales sanitarios.ABSTRACT: Recently, the new guidelines about cardiopulmonary resuscitation were published by the European Resuscitation Council (ERC). The same day, the Consejo Español de Resucitación Cardiopulmonar (CERCP) gave an announcement to declare the adhesion to these guidelines. This announcement brings up “the requirement to apply these European suggestions, both in the care services environment and in the formation environment”. Although most of the suggestions have had no changes with those suggestions published in 2010, the knowledge of these changes is needed to accommodate to the new knowledge. For this reason, this document pretends summarise the main changes in relation to the previous guidelines with the purpose to provide a first approach for healthcare professionals

CIBERER : Spanish national network for research on rare diseases: A highly productive collaborative initiative

Altres ajuts: Instituto de Salud Carlos III (ISCIII); Ministerio de Ciencia e Innovación.CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on rare diseases (RDs) currently consists of 75 research groups belonging to universities, research centers, and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical, and cellular research of RDs. This research is the basis for providing new tools for the diagnosis and therapy of low-prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this article, we intend to review CIBERER's 15-year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions toward the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to RD research

Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10

AKR1B10 is a human aldo-keto reductase (AKR) found to be elevated in several cancer types and in precancerous lesions. In vitro, AKR1B10 exhibits a much higher retinaldehyde reductase activity than any other human AKR, including AKR1B1 (aldose reductase). We here demonstrate that AKR1B10 also acts as a retinaldehyde reductase in vivo. This activity may be relevant in controlling the first step of retinoic acid synthesis. Up-regulation of AKR1B10, resulting in retinoic acid depletion, may lead to cellular proliferation. Both in vitro and in vivo activities of AKR1B10 were inhibited by tolrestat, an AKR1B1 inhibitor developed for diabetes treatment. The crystal structure of the ternary complex AKR1B10-NADP+-tolrestat was determined at 1.25-Å resolution. Molecular dynamics models of AKR1B10 and AKR1B1 with retinaldehyde isomers and site-directed mutagenesis show that subtle differences at the entrance of the retinoid-binding site, especially at position 125, are determinant for the all-trans-retinaldehyde specificity of AKR1B10. Substitutions in the retinaldehyde cyclohexene ring also influence the specificity. These structural features should facilitate the design of specific inhibitors, with potential use in cancer and diabetes treatments. © 2007 by The National Academy of Sciences of the USA.This work was supported by grants from Dirección General de Investigación (BMC2003-09606, BFU2005-02621, BFU2005-08686-C02-01, and FIS2005-00655) and Generalitat de Catalunya (2005SGR-00036 and 2005SGR-00112)Peer Reviewe

Copernicus Marine Service Ocean State Report, Issue 4

Editors: Karina von Schuckmann; Pierre-Yves Le Traon.-- Review Editors: Neville Smith (Chair); Ananda Pascual; Samuel Djavidnia; Jean-Pierre Gattuso; Marilaure Grégoire; Glenn Nolan.The authors would like to thank the Institut Cartogràfic i Geològic de Catalunya (ICGC) for providing data. Thanks are due to FCT/MCTES for the financial support to CESAM (UID/AMB/50017/2019), through national funds.Chapter 1: Introduction and the European Environment policy framework.-- CMEMS OSR4, Chapter 2: State, variability and change in the ocean.-- CMEMS OSR4, Chapter 3: Case studies.-- CMEMS OSR4, Chapter 4: Specific events 2018.-